Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 5/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.43 |
| ▸ | IGF1R | P08069 | 5/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640498 | 0.90 | BRAF (0.49) | BRAFMAPTTP53PKMYT1MEN1 | |
| SCHEMBL1641081 | 0.89 | BRAF (0.49) | BRAFMAPTTP53PKMYT1MEN1 | |
| SCHEMBL1639294 | 0.89 | BRAF (0.49) | BRAFMAPTTP53PKMYT1EGFR | |
| SCHEMBL1640568 | 0.88 | BRAF (0.49) | BRAFMAPTTP53PKMYT1MAPK14 | |
| SCHEMBL1641694 | 0.88 | BRAF (0.49) | BRAFMAPTTP53PKMYT1MEN1 | |
| SCHEMBL1641680 | 0.88 | BRAF (0.49) | BRAFMAPTTP53PKMYT1MEN1 | |
| SCHEMBL1640558 | 0.88 | LCLAT1 (0.45) | BRAFMAPTTP53MEN1KMT2A | |
| SCHEMBL1642030 | 0.88 | BRAF (0.64) | BRAFMAPTTP53PKMYT1EGFR | |
| SCHEMBL1641100 | 0.88 | BRAF (0.54) | BRAFMAPTTP53PKMYT1EGFR | |
| SCHEMBL3422428 | 0.87 | MAPK14 (0.48) | MAPTTP53MAPK14CDK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| EP-2231625-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009076140-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076140-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | PDXK, MAP3K1, MAP4K2 | BRAF 151/4885MAPT 1402/4885TP53 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.